Related Experiment Video
Updated: Jan 20, 2026
Aip1p Dynamics Are Altered by the R256H Mutation in Actin
Published on: July 30, 2014
Disease-Causing Mutations in SF3B1 Alter Splicing by Disrupting Interaction with SUGP1
Jian Zhang1, Abdullah M Ali2, Yen K Lieu3
1Department of Biological Sciences, Columbia University, New York, NY 10027, USA.
Abstract:
SF3B1, which encodes an essential spliceosomal protein, is frequently mutated in myelodysplastic syndromes (MDS) and many cancers. However, the defect of mutant SF3B1 is unknown. Here, we analyzed RNA sequencing data from MDS patients and confirmed that SF3B1 mutants use aberrant 3' splice sites. To elucidate the underlying mechanism, we purified complexes containing either wild-type or the hotspot K700E mutant SF3B1 and found that levels of a poorly studied spliceosomal protein, SUGP1, were reduced in mutant spliceosomes. Strikingly, SUGP1 knockdown completely recapitulated the splicing errors, whereas SUGP1 overexpression drove the protein, which our data suggest plays an important role in branchsite recognition, into the mutant spliceosome and partially rescued splicing. Other hotspot SF3B1 mutants showed similar altered splicing and diminished interaction with SUGP1. Our study demonstrates that SUGP1 loss is a common defect of spliceosomes with disease-causing SF3B1 mutations and, because this defect can be rescued, suggests possibilities for therapeutic intervention.
Insights
Mutations in SF3B1 cause splicing defects in myelodysplastic syndromes (MDS) by reducing SUGP1 levels. Restoring SUGP1 levels partially rescues these splicing errors, suggesting a therapeutic target.
Area of Science:
- Molecular Biology
- Genetics
- Cancer Research
Background:
- The SF3B1 gene encodes a crucial spliceosomal protein frequently mutated in myelodysplastic syndromes (MDS) and various cancers.
- The precise molecular defect caused by SF3B1 mutations remains largely unknown, hindering therapeutic development.
Purpose of the Study:
- To investigate the functional consequences of SF3B1 mutations on RNA splicing.
- To identify the underlying molecular mechanisms responsible for splicing defects in SF3B1-mutated MDS.
- To explore potential therapeutic strategies targeting SF3B1-associated splicing errors.
Main Methods:
- Analysis of RNA sequencing data from MDS patients with SF3B1 mutations.
- Purification and biochemical analysis of spliceosomal complexes containing wild-type and mutant SF3B1.
- Experimental manipulation of SUGP1 levels through knockdown and overexpression.
- Assessment of RNA splicing fidelity and branch-site recognition.
Main Results:
- SF3B1 mutants were confirmed to utilize aberrant 3' splice sites in MDS.
- Reduced levels of the spliceosomal protein SUGP1 were observed in spliceosomes with hotspot SF3B1 mutations.
- SUGP1 knockdown phenocopied the splicing errors observed in SF3B1 mutants.
- SUGP1 overexpression partially rescued splicing defects by promoting its incorporation into mutant spliceosomes.
Conclusions:
- Loss of SUGP1 function is a common defect in spliceosomes harboring disease-causing SF3B1 mutations.
- SUGP1 plays a critical role in branch-site recognition during RNA splicing.
- The rescue of splicing defects by SUGP1 restoration offers a potential avenue for therapeutic intervention in SF3B1-mutated cancers and MDS.
Related Concept Videos
02:18Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
01:32RNA Splicing
08:57Aip1p Dynamics Are Altered by the R256H Mutation in Actin
01:39Mutations
08:53A Reporter Based Cellular Assay for Monitoring Splicing Efficiency
05:51A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia